| Name | Title | Contact Details |
|---|
Make excessive sweat a thing of the past. Learn how miraDry® can permanently reduce underarm sweat in as little as one non-surgical treatment.
Tobira Therapeutics is a clinical-stage biopharmaceutical company developing cenicriviroc (CVC), an oral potent dual inhibitor of chemokine receptors CCR2 and CCR5. Tobira is initiating a Phase 2 clinical trial of cenicriviroc for the treatment of Nonalcoholic Steatohepatitis (NASH), a leading cause of cirrhosis and liver transplant. The company has also completed a Phase 2b clinical trial of cenicriviroc in 143 HIV-infected subjects, and the compound is positioned for Phase 3 studies as a novel, once daily, fixed-dose cenicriviroc/lamivudine backbone as part of combination HIV therapy. Tobira is backed by a syndicate of leading life science investors including Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners, Novo Ventures and Canaan Partners.
PharmaLinkFHI (PharmaLink) is the first full-service Clinical Research Organization (CRO) to integrate clinical and technological expertise in managing Phase I-IV clinical trials online in real time. Biopharmaceutical and medical device organizations